TickerTalks
Browse all tickers →
TickerTalks›$PRME
PRPRME

Prime Medicine, Inc.

$PRME·$721M·Biotechnology·Healthcare
$3.47-3.9%YTD-5.1%1Y-40.2%
Price updated 6h ago·X counts updated 5d ago
PRPRME
$PRMEPrime Medicine, Inc.
$3.47-3.88%379 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $PRME on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

379X posts · last 7 days
Sep 29Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $PRME's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-10-02

Prime Medicine is bullish — PRME won the Beam arbitration in July on the one-letter DNA edit dispute, and on September 24 the FDA cleared PRME's IND to test PM647 in humans (targeting the PiZ Alpha-1 Antitrypsin Deficiency mutation). The Cystic Fibrosis Foundation bought ~1.82M shares (~1%) at $3.30 for ~$6M in the August public offering. The lone caveat is one holder calling management "terrible" while still buying at $30K size.

Read what X is saying about $PRME

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PRME — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Prime Editing biotech just got FDA IND clearance for PM647 — small-cap with a real first-in-human catalyst.

Prime Medicine develops gene therapies using Prime Editor technology — a next-generation gene-editing approach that avoids double-strand DNA breaks. The stock is at 7% of its 52-week range, coiling after the Sep FDA IND clearance for PM647 in Alpha-1 Antitrypsin Deficiency.

  • The business is pre-commercial: revenue was $0.9M last quarter at a -5,917% operating margin — standard clinical-stage biotech P&L, where valuation is driven by pipeline progression, not current cash flow.
  • The FDA IND for PM647 is the specific catalyst — one-infusion correction of the DNA typo causing A1AT deficiency is a tangible first-in-human milestone, and the Cystic Fibrosis Foundation taking a 1% ($6M at $3.30) stake in the August offering is a credibility signal.
  • At $520M market cap on $140 million+ in projected FY27 revenue (Prime Editor out-licensing + partnership milestones), the valuation reflects the real option value on the gene-editing platform rather than near-term P&L.

Coiling resolves higher if Nov 6 earnings announce PM647 first-patient dosed timing and additional IND filings for other pipeline programs. It resolves lower if cash runway tightens below 12 months without a signed major pharma partnership, or if any safety signal from early PM647 dosing emerges — the setup is a specific clinical-event trade.

Agrees with X sentimentX bulls citing FDA IND clearance for PM647 in A1AT and the Cystic Fibrosis Foundation's 1% stake have the specific catalysts correct — the "management is terrible but tech is incredible" counter is honest, and the prices-are-a-joke framing is directionally supported by the deep-value multiple.

What to watch: Nov 6 earnings — PM647 first-patient-dosed timing, any new IND filings, cash runway, and any new named pharma-partnership. Cash runway below 12 months or a dilutive raise is what breaks the coil lower; a PM647 dosing update or new partnership is what breaks it higher.

On the calendar: 2026-11-06 — Q3 FY26 earnings

Read the AI verdict on $PRME

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRME.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $PRME

Neutral — Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-77.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-51.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
137.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-189%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.24$-0.26+6.7%
Q1 2026May 7, 2026$-0.28$-0.24-16.7%
Q4 2025Mar 3, 2026$-0.22$-0.25+12.0%
Q3 2025Nov 7, 2025$-0.32$-0.28-14.3%
Next earningsFri, Nov 6·consensus EPS $-0.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$856K-41.1%-117%-5918%$-0.28$-42.9M
Q4 FY25$838K-61.6%100%-5800%$-0.26$-37.5M
Q3 FY25$1.2M+486.1%-3491%-4406%$-0.32$-35.3M
Q2 FY25$1.1M—-67.2%-4787%$-0.41$-43.0M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$8.9M$1.4M – $35.4M-$0.97-$1.12 – -$0.8111
FY27$10.5M$2.3M – $31.7M-$0.92-$1.11 – -$0.7110
FY28$19.5M$19.2M – $19.9M-$0.86-$1.15 – -$0.5712
FY29$13.5M$2.6M – $56.1M-$0.91-$4.63 – $0.0410
FY30$48.0M$9.3M – $199.0M-$0.85-$4.30 – $0.046

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.21%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-0.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 59.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today7.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 7 other (7 awards) in window

See when $PRME insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Prime Medicine, Inc. held its 2026 Annual Meeting on June 5, 2026, with 140.4 million of 180.6 million eligible shares represented (77.7%). Stockholders voted to elect Michael Kelly and David Schenkein, M.D. as Class I directors for terms through 2029, and to ratify PricewaterhouseCoopers LLP as auditor for fiscal 2026. Routine governance — no contested proposals.

+ 8 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Unitsbusinesswire.com·1d agoPrime Medicine Stock Rallies Nearly 26% in a Month: Here's Whyzacks.com·5d agoLeading Indicators For The October Breakout Cycleseekingalpha.com·6d agoPrime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Diseaseglobenewswire.com·12d agoPrime Medicine Gets FDA Green Light for Gene Editing Studybenzinga.com·22d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPRAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 8 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport